April 2 (Reuters) - The U.S. Food and Drug

Administration's (FDA) website showed that four doses of Eli

Lilly's ( LLY ) diabetes drug, Mounjaro, would be available only

in limited amounts through April 2024 due to increased demand.

According to the health regulator's website, 7.5, 10, 12.5,

and 15 milligram doses of the injection will be in limited

availability, while lower doses of Mounjaro were shown to be

available.

Eli Lilly ( LLY ) did not immediately respond to a Reuters' request

for comment.

Soaring demand for a class of highly effective diabetes and

obesity drugs known as GLP-1 agonists, which suppress appetite

and promote a feeling of fullness, has led to supply constraints

for drugmakers such as Lilly and Danish drugmaker Novo Nordisk

.

Earlier this year, the FDA's website showed that 10, 12.5

and 15-milligram doses of the injection would have limited

availability through early March.

Lilly's Mounjaro has been approved for patients with type-2

diabetes to control their blood sugar levels since 2022.

The injection, which has the active ingredient tirzepatide,

gained the FDA's approval for weight loss under the brand name

Zepbound in the United States last year.